Compile Data Set for Download or QSAR
Report error Found 197 Enz. Inhib. hit(s) with all data for entry = 10327
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528049(US11180494, Example 1)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528137(US11180494, Example 14)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528138(US11180494, Example 15)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528139(US11180494, Example 16)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528140(US11180494, Example 17)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528142(US11180494, Example 19)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528143(US11180494, Example 20)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528144(US11180494, Example 21)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528145(US11180494, Example 22)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528146(US11180494, Example 23)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528147(US11180494, Example 24)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528149(US11180494, Example 25)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528150(US11180494, Example 26)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528151(US11180494, Example 27)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528152(US11180494, Example 28)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528153(US11180494, Example 29)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528154(US11180494, Example 30)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528155(US11180494, Example 31)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528156(US11180494, Example 32)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528157(US11180494, Example 33)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528160(US11180494, Example 36)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528161(US11180494, Example 37)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528165(US11180494, Example 41)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528174(US11180494, Example 50)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528175(US11180494, Example 51)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528176(US11180494, Example 52)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528182(US11180494, Example 62 | US11180494, Example 58)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528188(US11180494, Example 63)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528184(US11180494, Example 64 | US11180494, Example 60)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528185(US11180494, Example 65 | US11180494, Example 61)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528199(US11180494, Example 72)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528211(US11180494, Example 84)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528224(US11180494, Example 97)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528225(US11180494, Example 98)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528226(US11180494, Example 99)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528231(US11180494, Example 101)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528232(US11180494, Example 102)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528233(US11180494, Example 103)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528234(US11180494, Example 104)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528235(US11180494, Example 105)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528236(US11180494, Example 106)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528237(US11180494, Example 107)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528220(US11180494, Example 93 | US11180494, Example 108)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528239(US11180494, Example 109)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528240(US11180494, Example 111 | US11180494, Example 110)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528243(US11180494, Example 113)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528244(US11180494, Example 114)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528245(US11180494, Example 115)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528246(US11180494, Example 116)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528247(US11180494, Example 117)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 197 total ) | Next | Last >>
Jump to: